Overview
A recent study published in The Lancet Regional Health Southeast Asia estimates that typhoid fever imposed an economic burden of ₹123 billion in 2023. The bulk of this cost – 87 % – is linked to infections resistant to fluoroquinolone antibiotics.
Key Developments
- Fluoroquinolone‑resistant cases accounted for 87 % of total typhoid‑related expenses.
- Children <10 years old bore >50 % of the total cost, highlighting a disproportionate impact on the young.
- Households shouldered 91 % of the financial load; 70,000 families faced catastrophic health expenditure.
- Five high‑burden states – Maharashtra, Uttar Pradesh, Andhra Pradesh/Telangana, Tamil Nadu, West Bengal – contributed to 51 % of national costs.
- The study recommends adding the Typhoid conjugate vaccine to the national immunisation schedule.
Important Facts
The researchers, from the London School of Hygiene & Tropical Medicine and Christian Medical College, Vellore, combined epidemiological data, care‑seeking behaviour, and clinical outcomes to compute both direct (hospitalisation, drugs) and indirect (lost wages, school days) costs. Their analysis revealed that fluoroquinolone resistance not only prolongs illness but also inflates treatment expenses, especially for non‑hospitalised patients who often resort to costly private care.
Fluoroquinolones, once the first‑line therapy for severe typhoid, reduce fever within four days. Resistance forces clinicians to use newer, pricier antibiotics, thereby escalating the economic burden on families and the health system.
Exam Relevance
Understanding the nexus of antimicrobial resistance, health financing, and vaccine policy is crucial for GS‑3 (Health, Economy) and GS‑4 (Ethics) questions. The study underscores:
- How drug‑resistant infections strain public health budgets and household incomes.
- The role of evidence‑based advocacy in shaping immunisation policy.
- The importance of regional disparities—high‑burden states demand targeted interventions.
These points can be linked to topics such as “Antimicrobial resistance in India,” “Financing of health care,” and “National health programmes” in the UPSC syllabus.
Way Forward
Policymakers should consider a multi‑pronged approach:
- Accelerate the rollout of the TCV within the national immunisation schedule, prioritising the five high‑burden states.
- Strengthen antimicrobial stewardship to curb unnecessary fluoroquinolone use and promote susceptibility‑guided therapy.
- Expand financial risk protection mechanisms (e.g., insurance, cash transfers) to reduce catastrophic health expenditure among vulnerable families.
- Invest in water‑sanitation infrastructure to address the root cause of typhoid transmission.
Implementing these measures can lower the disease’s economic impact, improve child health outcomes, and align India’s health strategy with global antimicrobial‑resistance action plans.